PC
ROIV icon

Pier Capital’s Roivant Sciences ROIV Stock Holding History

Pier Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-227,093
Closed -$6.29M – 143
2026
Q1 		$6.29M Sell
227,093
-163,968
-42% -$4.21M 1.04% 49
2025
Q4 		$8.49M Sell
391,061
-3,623
-0.9% -$71.5K 1.35% 22
2025
Q3 		$5.97M Sell
394,684
-1,620
-0.4% -$20.1K 0.93% 53
2025
Q2 		$4.47M Sell
396,304
-31,839
-7% -$345K 0.68% 72
2025
Q1 		$4.32M Buy
428,143
+5,413
+1% +$58.5K 0.72% 69
2024
Q4 		$5M Sell
422,730
-7,178
-2% -$84.9K 0.71% 79
2024
Q3 		$4.96M Buy
429,908
+4,821
+1% +$54.9K 0.7% 80
2024
Q2 		$4.49M Buy
425,087
+96,905
+30% +$1.06M 0.67% 77
2024
Q1 		$3.46M Sell
328,182
-3,085
-0.9% -$33.3K 0.48% 90
2023
Q4 		$3.72M Sell
331,267
-3,736
-1% -$36.4K 0.53% 88
2023
Q3 		$3.91M Sell
335,003
-279,932
-46% -$3.16M 0.63% 79
2023
Q2 		$6.2M Sell
614,935
-1,004
-0.2% -$8.98K 0.89% 58
2023
Q1 		$4.55M Buy
+615,939
New +$5.07M 0.69% 73

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Pier Capital's ROIV Position: Q2 2026 in Review

Pier Capital sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 227,093 shares — an estimated $6.29M sold.

Pier Capital first reported a position in ROIV in Q1 2023 and held it in 13 quarters. The position peaked at $8.49M in Q4 2025. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Pier Capital reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
  • Pier Capital sold 227,093 Roivant Sciences shares in Q2 2026, an estimated $6.29M.
  • Pier Capital first reported a position in Roivant Sciences in Q1 2023 and held it in 13 quarters.
  • Pier Capital's Roivant Sciences position peaked at $8.49M in Q4 2025.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Pier Capital's 13F filing for Q2 2026, filed 5 Aug 2026.